AQR Capital Management LLC increased its position in shares of Mylan NV (NASDAQ:MYL) by 11.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,247,227 shares of the company’s stock after buying an additional 1,111,009 shares during the quarter. AQR Capital Management LLC owned about 2.18% of Mylan worth $213,473,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Advisory Services Network LLC grew its stake in shares of Mylan by 170.0% during the second quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock worth $29,000 after purchasing an additional 957 shares in the last quarter. NuWave Investment Management LLC grew its stake in shares of Mylan by 1,111.0% during the second quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock worth $42,000 after purchasing an additional 2,011 shares in the last quarter. Rational Advisors LLC boosted its stake in Mylan by 1,111.0% in the second quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock valued at $42,000 after acquiring an additional 2,011 shares in the last quarter. Signaturefd LLC boosted its stake in Mylan by 271.8% in the second quarter. Signaturefd LLC now owns 3,376 shares of the company’s stock valued at $64,000 after acquiring an additional 2,468 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in Mylan by 22.5% in the second quarter. Rockefeller Capital Management L.P. now owns 3,755 shares of the company’s stock valued at $71,000 after acquiring an additional 689 shares in the last quarter. 84.75% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Sjoerd S. Vollebregt purchased 10,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were bought at an average price of $19.11 per share, with a total value of $191,100.00. Following the completion of the purchase, the director now directly owns 18,258 shares in the company, valued at approximately $348,910.38. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Mark purchased 4,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were bought at an average cost of $20.97 per share, for a total transaction of $83,880.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at $83,880. The disclosure for this purchase can be found here. Insiders bought 83,859 shares of company stock worth $1,628,752 over the last quarter. Company insiders own 0.81% of the company’s stock.
MYL traded up $0.43 on Friday, hitting $18.90. 3,968,474 shares of the company were exchanged, compared to its average volume of 5,173,042. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.37. The business’s fifty day moving average is $19.86 and its 200 day moving average is $20.98. Mylan NV has a fifty-two week low of $16.63 and a fifty-two week high of $37.56. The firm has a market capitalization of $9.51 billion, a P/E ratio of 4.13, a price-to-earnings-growth ratio of 0.88 and a beta of 1.80.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.08. The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.82 billion. Mylan had a net margin of 0.30% and a return on equity of 18.93%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.07 earnings per share. Analysts forecast that Mylan NV will post 4.27 EPS for the current fiscal year.
Several equities analysts have issued reports on the stock. Citigroup set a $26.00 price objective on shares of Mylan and gave the company a “buy” rating in a research note on Wednesday, July 31st. Wolfe Research assumed coverage on shares of Mylan in a research note on Friday, July 19th. They issued an “outperform” rating and a $27.00 price objective for the company. TheStreet downgraded shares of Mylan from a “c-” rating to a “d+” rating in a research note on Friday, August 2nd. SunTrust Banks upped their target price on shares of Mylan from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of Mylan in a report on Tuesday, July 30th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. Mylan currently has a consensus rating of “Buy” and a consensus target price of $30.03.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: What does an outperform rating mean?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.